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Reactive gliosis is a general response of
mammalian central nervous system (CNS) to
injury. Traditionally, the glial scar has been
viewed as the major obstacle to axon regenera-
tion (and hence, to host-transplant integration),
but a direct test of this idea has been hampered
by the lack of an in vitro model of reactive glia.
Cultured perinatal astrocytes, treated with di-
butyryl-cyclic-AMP (dBcAMP), had a morpho-
logy and intermediate filament content reminis-
cent of reactive astrocytes evoked by injury.
However, their immunohistochemical and
neurite outgrowth-promoting properties were
much closer to those untreated astrocytes in cul-
ture than to reactive astrocytes in vivo
(Bovolenta P, Wandosell F, Nieto-Sampedro M,
Res Neurol Neurosci 1991; 2: 221-228). Our
observations strongly suggest that diBcAMP
treatment leads, at best, to a morphological
model of reactive cells, lacking many properties
of reactive astrocytes generated in vivo.
Accordingly, we developed an alternative model,
based on the fact that plasma membranes can be
easily purified, so that they conserve many of the
surface properties of the cell. Myelin-free
plasma membranes, purified from normal and
gliotic tissue by a combination of differential and
sucrose gradient centrifugation, were used as
cell culture substrate for i) neurite initiation and
ii) neurite choice of growth substrate.
To test neurite initiation, purified plasma
membranes alone or mixed with laminin (LN)
were adsorbed onto polylysine (PLL)-coated
tissue culture dishes. Neurite outgrowth from rat
embryo explants or dissociated cells (septum,
hippocampus, or dorsal root ganglia), was
determined conventionally, using as controls
purified myelin, that strongly inhibited neurite
outgrowth, and membranes from cultured type 1
astrocytes, that were powerful neurite growth
promoters. For the substrate choice experi-
ments, neurite outgrowth was initiated by excess
PLL-LN and the growing neurites were faced
with a substrate coated with PLL-LN and the
test substance. The behavior of the growth cone,
when reaching the boundary between the two
substrates, was recorded.
Normal brain tissue membranes (NTM) pro-
moted neurite initiation and provided a per-
missive substrate for neurite extension. In
contrast, membranes purified from isomorphic
gliotic tissue inhibited neurite initiation and
repelled growing neurites. The inhibitory activity
was solubilized using a mild detergent and was
subsequently purified and characterized using
conventional biochemical techniques, under
denaturing conditions. The activity resided in a
proteoglycan fraction of molecular weight 150-
200 kDa that was heat, trypsin, lipase and gly-
cosidase resistant, but glycosaminoglycan lyase-
sensitive. Digestion with a combination of
heparinase I and chondroitinase ABC revealed
core proteins of apparent molecular weight 66-
68 kDa and 48 kDa. The expression of the 48
kDa protein underwent a large specific increase
in injured vs normal brain tissue. The inhibitory
proteoglycan was structurally and immunolo-
gically different from the myelin inhibitors.
When presented as a surface bound molecule it
prevented neurite initiation. When added in a
soluble form to already growing neurites, it
induced their retraction. Purified microglial
membranes contained neurite inhibitory activity
with properties similar to those of the
proteoglycan purified from gliotic tissue.
Furthermore, a polyclonal antibody to the in-
hibitory fraction appeared to immunostain
microglial cells in culture. CNS tissue, it appears,
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always contains both neurite-promoting and
neurite-inhibiting molecules. It is the balance of
these two activities that determines how good an
environment for neurite outgrowth is provided
by the CNS under given physiological conditions.
Our results provide the first cellular and
molecular evidence in support of the classical
view that, in the mammalian CNS, injury evoked
gliosis enhances the expression of molecules
capable of preventing nerve regeneration.
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